uniQure N.V.
QUREuniQure N.V. is a biotechnology company focused on developing gene therapy treatments for genetic and other life-threatening diseases. Founded in the Netherlands, it specializes in delivering gene therapies using adeno-associated virus (AAV) vectors to address rare, serious conditions such as hemophilia and neurological disorders.
Company News
uniQure N.V. announced the pricing of an underwritten public offering of 4,945,055 ordinary shares at $45.50 per share, generating approximately $225 million in gross proceeds. The offering is expected to close on June 25, 2026. The company is advancing gene therapies for hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabr...
Numero AI has acquired Royu in an undisclosed cash-and-stock transaction to combine AI-first fintech capabilities for enterprise finance operations. The merger brings together Royu's engineering expertise with Numero's finance domain knowledge to expand agentic AI systems across accounting close, reconciliation, reporting, order-to-cash, and tech...
The Schall Law Firm is seeking investors who purchased uniQure N.V. securities between September 24, 2025, and October 31, 2025, for a class action lawsuit alleging securities fraud. The company allegedly made false and misleading statements regarding FDA approval for its Pivotal Study and misrepresented the timeline for its BLA submission, resul...
Hagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorting comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FD...
Hagens Berman is investigating uniQure (QURE) for allegedly misrepresenting FDA interactions and using an unapproved study design for its AMT-130 gene therapy candidate. FDA officials publicly criticized the company for distorted comparisons and downplaying sham surgery requirements. The stock plunged 49% on November 3, 2025, when the lack of FDA...
